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Edited by Beat ImhofAbstract The mode of action of annexin A1 (ANXA1) is poorly
understood. By using rapid subtraction hybridization we studied
the eﬀects of human recombinant ANXA1 and the N-terminal
ANXA1 peptide on gene expression in a human larynx cell line.
Three genes showed strong downregulation after treatment with
ANXA1. In contrast, expression of CCR10, a seven transmem-
brane G-protein coupled receptor for chemokine CCL27 involved
in mucosal immunity, was increased. Moreover the reduction in
CCR10 expression induced by ANXA1 gene deletion was res-
cued by intravenous treatment with low doses of ANXA1. These
ﬁndings provide new evidence that ANXA1 modulates gene
expression.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Annexin A1 (ANXA1) is a 37 kDa member of a family of
Ca2+-regulated lipid-binding proteins [1]. Functional studies
have identiﬁed roles for ANXA1 and its N-terminal domain
[2,3] in the regulation of inﬂammation [4], the cell cycle [5]
and as a mediator of glucocorticoid action on the release of cor-
ticotrophin (ACTH) from the anterior pituitary gland [6,7].
Many of the regulatory actions ofANXA1 in these systems have
been shown to emerge promptly, i.e., within minutes to hours of
contact with the protein [6]. Whilst some have been ascribed to
the ability of ANXA1 to act intracellularly to disrupt signalling
cascades [8], others appear to reﬂect interactions with cell sur-
face receptors [9–11]. Recent studies suggest that members of
the formyl peptide receptor (FPR) family of G-protein coupled
receptors are particularly important in this regard [12,13]. Three
members of this receptor family have been identiﬁed in human,
termed FPR, FPRL1 and FPRL2. Receptor-speciﬁc ligands are
not yet available, but FPR is highly sensitive to the bacterial
peptide formyl-Met-Leu-Phe (fMLP), while FPRL1 shows
some selectivity for lipoxin A4, a lipid metabolite, in addition
to responding to high concentrations of fMLP [14].*Corresponding author. Fax: +44 208 3838032.
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doi:10.1016/j.febslet.2006.01.072Despite the evidence that ANXA1 might inﬂuence cellular
responsiveness, the possibility that ANXA1 regulates gene
expression has received scant attention. Interestingly however,
the recently generated ANXA1 knockout mouse shows signif-
icant alterations in the expression of a number of gene prod-
ucts associated with inﬂammation [15,16], a ﬁnding that
concurs with earlier reports that ANXA1 reduces the expres-
sion of inducible nitric oxide synthase [17].
We have used rapid subtraction hybridisation (RaSH) [18]
to investigate the eﬀects of ANXA1Ac2–26 on gene expression
in a human cell line of epithelial origin. In addition, we have
compared the eﬀects of hrANXA1 and ANXA1Ac2–26 with
those of fMLP (a bacterial peptide) and the stable analogue
of lipoxin A4 [15-epi-16-(para-ﬂuoro)-phenoxy-LXA4-methyl
ester, ATLa-ME], an arachidonic acid metabolite, in order
to explore the role of the FPR family in eﬀecting the response
to ANXA1. The data obtained from the cell line in vitro have
been evaluated in vivo by studies on Anxa1 null mice. Our
ﬁndings strongly support a role for ANXA1 in the regulation
of gene expression, particularly those genes concerned with the
inﬂammatory response.2. Materials and methods
2.1. Drugs
Human recombinant annexin A1, [19] was produced, puriﬁed and
tested by SDS–PAGE for the presence of cleaved forms which were
not detected, by Scientiﬁc Proteins, Witterswil, Switzerland. Further-
more, the recombinant protein did not show any phosphorylation at
the N-terminal as reported previously [19]. HumanANXA1Ac2–26 (acet-
ylated peptide at the N-terminal) was synthesized in the Advanced Bio-
technology Centre, Imperial College London, UK. The peptide fMLP
was purchased from Sigma (Sigma–Aldrich Corp., Poole, Dorset,
UK) and 15-epi-16-(para-ﬂuoro)-phenoxy-ATLA-methyl ester (ATLa,
the methyl ester of lipoxin A4) was a generous gift from Professor C.
Serhan (Harvard Medical School, Boston, USA). The doses of acety-
lated peptide (ANXA1Ac2–26; 2 lM) were chosen on the basis of previ-
ous studies, performed both in vitro and in vivo, in which we showed
that comparable biological activity were obtained when the ratio be-
tween fMLP or ATLa and ANXA1Ac2–26 was 1:20 [13,20] furthermore
such molar ratio was of 1:15 between the entire recombinant ANXA1
and the peptide Ac2–26 as described previously [21].
2.2. Cell culture
The Hep-2 cell lines were derived from a human larynx epidermoid
carcinoma cells (ATCC Rockville, MD, USA) and used for RaSH
analysis. The PDFS cell line derived from a clinically non-functioning
pituitary macroadenoma was used to conﬁrm and compare the analy-
sis performed on Hep-2 cells (see supplement Table 2) [22].blished by Elsevier B.V. All rights reserved.
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Male Anxa1-null mice aged approximately 4 months old [15] and
weighing 30 ± 4 g were used together with age- and sex-matched wild
type controls. All animals were fed on a standard chow pellet diet.
All procedures were carried out under licence in accordance with the
UK Animals (Scientiﬁc Procedures) Act, 1986. For tissue collection
the animals were killed by cervical dislocation and their lower back re-
gion was shaved. Longitudinal fragments of the dorsal skin (after shav-
ing), trachea and ileum were obtained from each mouse (6 animals per
tissue) and frozen immediately in liquid nitrogen for subsequent
extraction of RNA and protein.
Anxa1 null mice were injected intravenously via the lateral tail vein
with hrANXA1 (10 ng/mouse), ANXA1Ac2–26 (14 ng/mouse) or a cor-
responding volume of the saline vehicle (100 ll). Mice (three animals
per treatment) were killed with CO2, 24 h after drug administration,
and tissues collected exactly as described above.
2.4. Rapid subtraction hybridization (RaSH) and RT-PCR analysis
Hep-2 cells were plated at a concentration of 106 cells/in six well
plates (Corning Incorporated, NY, USA) and 24 h later in culture,
stimulated with ANXA1Ac2–26 (2 lM; 72 h). Total RNA isolated by
RNeasy (Qiagen, West Sussex, England) from control and treated cells
were used for double-stranded cDNA synthesis using a standard pro-
tocol [23]. The DNA was then digested and mixed with the adaptors
XPDN-14/XPDN-12 (Sigma Genosys; ﬁnal concentration 20 lM) as
described by Jiang et al. [18]. 100 ng tester cDNA (e.g., untreated cells)
was mixed with 5 lg driver cDNA (e.g., ANXA1Ac2–26 treated cells, see
also Table 1 ) in hybridization solution [18,24]. After extraction and
precipitation the hybridization mixtures (1 lg) were ligated to an XhoI
digested pCDNA3 plasmid and transformed in competent bacteria.
Bacterial colonies were selected randomly and ampliﬁed by PCR.
The sequences of these clones were determined using the automated cy-
cle sequencer in the Advanced Biotechnology Centre, Imperial College
London. Sequences were compared with the NCBI nucleotide bank
(GenBank) allowing identiﬁcation of any genes up or down regulated.
Experiments were then set up (n = 3) in the same conditions described
above and RT-PCR with speciﬁc oligonucleotides (supplementary data
Table 1) for the genes identiﬁed by RaSH was performed.
2.5. Semi quantitative RNA analysis
We ﬁrst determined the linear range of ampliﬁcation (25, 20, 35, 40
cycles) of cDNA using each of the primer sets. Ampliﬁcation was with-
in the linear range for all genes studies when 35 PCR cycles were used
and this level of ampliﬁcation was therefore used in all further studies.
For each sample 5 ll of the PCR ampliﬁcation products was analysed
on 2% agarose gels and stained with ethidium bromide. The intensities
of the bands were compared to GAPDH in each sample and evaluated
using the Image Master Software (SYDR-1990, SYNGENE, USA).
2.6. Western blot analysis
Expression of CCR10 (GPR2) protein (15 lg) was examined in the
cell lines and murine tissue extracts by SDS–PAGE, then transferred
electrophoretically to nitrocellulose paper [25]. The blots were incu-
bated overnight at 4 C in incubation buﬀer in presence of an anti-
CCR10 antiserum (diluted 1:1000, goat anti-mouse polyclonal,
Abcam; or anti human CCR10 diluted 1:1000, Imgenex San Diego,
CA, USA). Immunoreactive protein bands were detected by chemilu-
minescence (GE Healthcare, UK) after incubation with secondaryTable 1
Genes isolated by RaSH
Symbol Locus
Upregulated 100 ng of tester
(ANXA1Ac2–26 treated cells)
versus 5 lg of driver (untreated cells)
CCR10 (NM_016602) 2826
Downregulated 100 ng of tester
(ANXA1Ac2–26 treated cells)
versus 5 lg of driver (untreated cells)
TIFA (NM_052864) 92610
FARSLA (NM_004461) 2193
ITGB1BP1 (NM_004763) 9270antibody (rabbit anti-goat peroxidase; 1: 100000, Biomeda; or goat
anti-rabbit peroxidase conjugated antiserum, 1:25000, Sigma–Aldrich
Corp.). The blots were then scanned and analyzed (HP Scanjet 5200
with Adobe Photodeluxe Business Edition, version 1.1; Cupertino,
CA). The intensities of the bands were compared to b-actin (mouse
monoclonal 1:5000, Abcam).
2.7. FACS analysis
For detection of FPR and FPRL1 on the cell surface of Hep-2 and
PDFS cells, aliquots of suspensions of the cells (105 cells in 100 ll) were
added to a 96-ﬂat well plate in triplicate and incubated at 4 C for 1 h
in the presence or absence (controls) of either: (a) a monoclonal anti-
human FPR antibody (1:100, BD Pharmingen) or mouse IgG1 clone
NOPC-21 (isotype-matched control antibody 1:100, BD Pharmingen,
UK) or (b) a rabbit anti-human FPRL1 polyclonal antiserum raised
against the peptide TVWLKEMLFYGKYKIIDILVNP from the 3rd
extracellular domain of the receptor (1:100, Neosystem Strasburg,
France). Non-speciﬁc binding was minimized by the addition of hu-
man IgG (1.6 mg/ml, Roche Diagnostics, Lewes, UK). After incuba-
tion with the primary antiserum, the cells were incubated on ice for
30 min with FITC-conjugated rabbit anti-mouse or sheep anti-rabbit
IgG (1:300, Serotec, Kidlington, Oxford, UK). The cell surface ﬂuores-
cence was analyzed immediately by ﬂow cytometry using a Becton
Dickinson FACScan II analyzer. At least 10000 cells per sample were
counted. The data were analyzed as units of ﬂuorescence measured in
the FL1 channel (mean ﬂuorescence intensity). A similar method was
used to detect and quantify expression of the cell surface receptor
CCR10 (GPR2) using a goat anti-rabbit polyclonal antibody to
CCR10 (GPR2, 1:100, Imgenex San Diego, CA, USA) as a probe
and FITC-conjugated sheep anti-rabbit IgG (1:300, Serotec) for
detection.
2.8. Statistical analysis
Statistical signiﬁcance was assessed by ANOVA followed by Bonfer-
roni’s t test, and P < 0.05 was taken as statistically signiﬁcant.3. Results and discussion
3.1. Annexin A1 modulates gene expression in cell line
Subtractive hybridisation performed on the human cell line
Hep-2, identiﬁed three genes, which were downregulated by
hrANXA1 (100 nM) and ANXA1Ac2–26 (2 lM) treatment.
The ﬁrst was ITGB1BP1 (previously named ICAP-1A, Table
1 and Fig. 1) a protein speciﬁcally associated with the b1 cyto-
plasmic domain of integrins [26] containing putative phosphor-
ylation sites. The phosphorylated form probably impairs cell
adhesion and spreading [27], but over-expression of ITGB1BP1
stimulates cell migration [28]. Thus, the ability of ANXA1 to
impair monocytes on the endothelium in vitro [21] may be med-
iated, at least in part, through ITGB1BP1 downregulation.
Since ANXA1 and ANXA1-derived peptides are potential
ligands for members of the formyl peptide receptor (FPR)
family, we explored the potential role of these receptors inID Function
A G protein coupled receptor for chemokine
CCL27 mostly involved in T cell mediated skin inﬂammation
A TRAF2 binding protein involved in the TNF-mediated
signalling
A tRNA synthetase family expressed in a cell cycle
stage and diﬀerentiation-dependent manner
Accessory protein for the integrin beta 1
Fig. 1. Comparison of the eﬀect of ANXA1 and FPRs ligands: fMLP and ATLa on ITGB1BP1, TIFA and FARSLA in Hep-2 genes isolated by
RaSH. Cells were plated and treated as reported for RaSH analysis. After 72 h of stimulation with (A) ANXA1 (100 nM) or ANXA1Ac2–26 (2 lM) or
(B) fMLP (100 nM) and ATLa (100 nM) total RNA was extracted and RT-PCR performed using speciﬁc oligos for the above genes. Semi-
quantitative normalization was performed using GAPDH expression. The data are representative of six independent experiments.
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First, we used RT-PCR and FACS analysis to determine
whether Hep-2 cells express FPR and FPRL1. Our data dem-
onstrated mRNA and protein for both receptors in Hep-2 cells
(Fig. 2A and B). Subsequently, we used ligands of FPR and
FPRL1, fMLP and the lipoxin A4 analogue (ATLa), to ex-
plore whether activation of these receptors modulated the
expression of ITGB1BP1 (Fig. 1B and Table 3B supplementFig. 2. Hep-2 cells express both FPR and FPRL1 receptors. (A) RT-PCR an
the entire coding sequences for FPR and FPRL1, respectively. Lanes 2 and 3
FACS analysis of FPR and FPRL1 expression on the surface of the cells. Tdata). Neither fLMP nor ATLa, ligands for FPR and FPRL1,
modiﬁed the expression of ITGB1BP1 (Fig. 1B). Although we
cannot exclude the possibility that higher concentrations of
these compounds may have been eﬀective they would be ex-
pected to act at the concentrations tested [13] and indeed have
been shown to modify the expression of other genes in this
study. We therefore suggest that the regulatory actions of
ANXA1 and ANXA1Ac2–26 on the expression of ITGB1BP1alysis lanes 1 and 4 represent the control ampliﬁed plasmids containing
ampliﬁed product in Hep-2 cells for FPR and FPRL1 respectively. (B)
he data are representative of three independent analyses.
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FPRL1.
A second gene downregulated by both hrANXA1 and AN-
XA1Ac2–26 was a phenylalanine-tRNA synthetase (FARSLA).
Unlike ITGB1BP1 this gene was also downregulated by fMLP
and ATLa, suggesting a role for the FPR family in mediating
the response (Fig. 1A and B). In vivo FARSLA is expressed in
a tumour-selective, cell cycle stage and diﬀerentiation-depen-
dent manner and its expression is augmented in tumourigenic
versus non-tumourigenic variant of the same cell line [29].
Interactions between ANXA1 and aminoacyl-tRNa synthase
have been reported in patients with dermatomyositis [30] and
between ANXA1 and tryptophanyl-tRNA synthetase [31]. To-
gether, these results raise the possibility that ANXA1 plays a
role in cell transformation as well as in protein translation
and may explain why it is highly expressed in some cancers
and not in others [32]. Interestingly, it has been proposed that
ANXA1 and tRNA synthase share some physiological role in
process related to myositis and immune response [31].Fig. 3. CCR10 expression in Hep 2 cells. RT-PCR analysis of CCR10 expre
for 72 h. The data are representative of six independent experiments.
Fig. 4. Western blot and FACS analysis of CCR10 expression on Hep-2 ce
protein cell extract from treated or untreated cells were analysed by Wester
number of cells) showing the data from one of three independent experimenA third gene downregulated by ANXAAc2–26 and fMLP, but
not by ANXA1 or ATLa (Fig. 1A and B) was a TRAF-inter-
acting protein with a forkhead-associated domain termed
TIFA or T2BP. Although merely speculative, as we do not
know how the acetylation may aﬀect the structure and func-
tion of the peptide, the downregulation of TIFA suggests that
ANXA1 may modulate inﬂammatory processes via TNFa and
TIFA, supporting our previous ﬁndings on the role of ANXA1
in systemic endotoxemia [33]. The data on the full protein
(hrANXA1) or ATLa (ligand of FPRL1 receptor), which did
not aﬀect the expression of this gene, suggest that the full-
length protein (hrANXA1) and the N-terminal peptide (AN-
XA1Ac2–26) act via diﬀerent mechanisms and thus support a
preferential binding of ANXA1 to FPRL1 receptor [13]. We
have recently published data on the diﬀerential eﬀects of the
full-length protein and its peptide in the ﬁrm adhesion of hu-
man PMNs on the endothelium under ﬂow [20] and the results
demonstrated here reinforce the dichotomy in the biological
activity of the acetylated peptide versus the entire molecule.ssion after stimulation with ANXA1, ANXA1Ac2–26, fMLP and ATLa
lls treated with recombinant hANXA1 and ANXA1Ac2–26. (A) Total
n blot. (B) FACS analysis: histogram (intensity of ﬂuorescence versus
ts which all showed similar results.
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ANXA1 (which is strongly expressed in epithelial cells and
skin [34]), had a positive eﬀect on the expression of theFig. 5. CCR10 expression in Anxa 1 null mice. Left: RT-PCR analysis and r
Anxa1 null and wild type control mice. Histograms represent a semi-quant
relative WT.CCR10 gene (Table 1), a skin homing receptor for chemokine
CCL27 [35]. This eﬀect was mimicked by ANXA1Ac2–26, fMLP
and ATLa (Fig. 3 A and B), supporting a role for the FPRight: Western blot analysis of CCR10 in trachea, skin and ileum from
itative analysis performed on 6 mice per genotype, * P < 0.005 versus
1436 F.C. Rodrigues-Lisoni et al. / FEBS Letters 580 (2006) 1431–1438family in mediating the positive eﬀect of ANXA1. Support for
a role of ANXA1 in CCR10 gene regulation was provided by
the Western blot and FACS analysis of the protein expression
and membrane localisation (Fig. 4A and B) indicating the po-
tential for a ligand binding activity.
3.2. Analysis of CCR10 expression in vivo
Our studies on Anxa1-null mice and wild type controls re-
veal a marked reduction in CCR10 expression in the Anxa1-
null mice versus control (Fig. 5) and show that this is reversed
by treatment with hrANXA1 or ANXA1Ac2–26 (Fig. 6). How-Fig. 6. Exogenous recombinant ANXA1 augments the expression of CCR1
analysis Right panel: Western blot of CCR10 in trachea and ileum of wild typ
or ANXA1Ac2–26 (10 ng/mouse, and 14 ng/ mouse, respectively, iv, 24 h befor
experiments performed on three animals per group.ever Anxa1 null mice did not show any phenotype that could
readily be linked to downregulation of CCR10 and further
studies are necessary to explore the signiﬁcance of these ﬁnd-
ings. However, our own data (John et al. manuscript in prep-
aration) and a recent report showing the LPS susceptibility of
the Anxa1 null mice [36] open new avenues on the possible sig-
niﬁcance of changes in CCR10 expression.
As ANXA1 is commonly viewed as an anti-inﬂammatory
protein and CCL27 is pro-inﬂammatory, it might have been
predicted that ANXA1 would downregulate CCR10 expres-
sion. However recent studies have reported that CCR100 in trachea and ileum from Anxa 1 null mice. Left panel: RT-PCR
e (WT) and Anxa1 null mice treated with human recombinant ANXA1
e animals were killed). The data are representative of two independent
F.C. Rodrigues-Lisoni et al. / FEBS Letters 580 (2006) 1431–1438 1437induction on pathogen-speciﬁc IgA-secreting B cells may be an
important factor for successful protection following local
mucosal infection [37].4. Conclusions
Taken together, the data provide new evidence that ANXA1
modulates gene expression. The mechanisms responsible re-
quire further investigation. While our data support a role for
the FPR family in mediating some of the eﬀects, the failure
of fLMP and ATLa to suppress ITGB1BP1 suggest other
mechanisms are involved. Furthermore, the dissociation
between the activities of hrANXA1 and ANXA1Ac2–26
support the premise that the actions of ANXA1, but not
ANXA1Ac2–26, are akin to those of the FPRL1 ligand LXA4.
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